Takeda’s Official Ground-Breaking on its First “Net Zero Carbon Emissions” Building in Singapore

Takeda’s Official Ground-Breaking on its First “Net Zero Carbon Emissions” Building in Singapore

Takeda recently held a ground-breaking ceremony for its first ‘Net Zero Carbon Emission’ building in its global manufacturing and supply network in Woodlands, Singapore. The building will follow Singapore Green Mark Zero Energy certification scheme. It is a $14 million USD expansion of the Woodlands facility and a first-of-its kind in the biotechnology industry in Singapore.

Full Article

Singapore – On September 23rd 2021, a delegation of Takeda’s global executive team in the presence of various partners and guests from Singapore, announced the official ground-breaking of its first ‘net zero carbon emission’ building in Singapore. The building is a first in Takeda’s global manufacturing and supply network in Woodlands, Singapore to follow the Singapore Green Mark Zero Energy certification scheme. The building, a $14 million USD expansion of Takeda’s manufacturing operations in Singapore, is also the first-of-its-kind investment within Singapore’s biopharmaceutical sector.

Located next to Takeda’s biologics manufacturing plant in JTC’s Woodlands Wafer Fab Park, Takeda’s new zero energy building is planned for occupancy by 2022.

 “The ground breaking of our first zero energy building demonstrates Takeda’s commitment to deliver on our environmental goals,” said Thomas Wozniewski, global manufacturing and supply officer of Takeda. “Takeda achieved carbon neutrality in 2020, now we are focused on our next step to become net zero by 2040. We are honoured to have the opportunity to work with our partners in the region and to support the Singapore government’s efforts in tackling climate change.”

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.

NEWS PROVIDED BY
Takeda Pharmaceutical Company Limited
 Sep 23, 2021
View Original Content

Comments

Leave A Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

bag